Glycopyrronium/Formoterol: A Review in COPD

Area of Science:

• Pharmacology and Therapeutics
• Respiratory Medicine

Background:

• Chronic Obstructive Pulmonary Disease (COPD) requires effective long-term management strategies.
• Fixed-dose combinations of bronchodilators offer potential for improved patient outcomes.
• Pressurized Metered Dose Inhalers (pMDIs) with advanced delivery technology are crucial for COPD treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of glycopyrronium/formoterol (Bevespi Aerosphere) in COPD patients.
• To compare glycopyrronium/formoterol pMDI with its monocomponents, placebo, and tiotropium.
• To assess glycopyrronium/formoterol against umeclidinium/vilanterol in COPD patients.

Main Methods:

• The PINNACLE trials assessed lung function improvements over 24 and 52 weeks.
• The AERISTO trial compared glycopyrronium/formoterol pMDI with umeclidinium/vilanterol DPI.
• Forced expiratory volume in 1 second (FEV1) was a key efficacy endpoint.

Main Results:

• Glycopyrronium/formoterol demonstrated significantly greater lung function improvements than monocomponents and placebo in PINNACLE trials.
• Over 52 weeks, it showed superiority to monocomponents and open-label tiotropium.
• In AERISTO, it was non-inferior for peak FEV1 but not for trough FEV1 compared to umeclidinium/vilanterol.

Conclusions:

• Glycopyrronium/formoterol pMDI, utilizing co-suspension delivery technology, is effective for COPD maintenance treatment.
• The combination therapy was generally well-tolerated, with mild to moderate adverse events.
• This formulation represents a valuable addition to the therapeutic options for COPD patients.